UK- India Science Bridge: BioPharm 2020

Transcription

1 DST INDIA - RESEARCH COUNCILS UK UK- India Science Bridge: BioPharm 2020 Entrepreneurial Opportunities for Indian and UK Scientists in the Pharmaceutical and Biotechnology Industries UK-India Impact Symposium Wednesday 8 th December 2010

2 The goal of BioPharm 2020 Science Bridge is to exploit synergies between scientists and industries in India and the UK to create a stepchange in collaborative innovation in regenerative medicine and drug discovery.

3 There are 3 key areas where we will deliver external impact Research A number of R&D projects are underway in drug delivery, bioprocessing and tissue repair with student exchanges that have produced initial disclosures. Industry To strengthen industrial engagement, we have delivered a number of successful events which have lead to international internships with companies. We can highlight a recent MBA internship with a global pharmaceutical company, undertaking a comparison of outsourcing of R&D between China, India and UK. New Businesses UK-India Biotechnology Business Plan competition was launched in 2010 to encourage and support entrepreneurship in the healthcare and pharmaceutical sector through a range of on-line tools including videos from experts Creation of real businesses which bring fresh ideas and innovation to the market.

4 Marketing of competition to UK and Indian Scientists invited to compete; audience directed to Teams complete and submit a short business plan (max. 5 pages) using various on-line tools, including narrated presentations (Master-Classes) The shortlisted teams invited to further develop their business plans, with mentors, over a 3 month period. High profile panel of judges review business plans; teams make a 20 minute pitch and showcase idea in a non disclosing poster session Winning teams awarded with a package of benefits to assist them in setting up a new business entity UK Prize: 20,000 cash award plus 1 year business start up facilities India Prize: Rs. 5 Lakhs cash award plus 2 years incubation facilities

5 The Outcome Platelet Solutions (UK Award Winners 2010) Developed a simple to use test kit to improve the monitoring and care of heart attack and stroke patients by testing the effectiveness of anti-platelet agents. The test will tell doctors whether to adjust the dose of the medicine or prescribe a different medicine reducing the risk of further events in patients. A spin out company is expected to launch by the end of A team member from Platelet Solutions has won a further accolade with an Enterprise Fellowship Award, to extend the companies blood testing capabilities to a higher level. Chalk2Salt (India Award Winners 2010) Developed a more stable solid-state form an anti-cancer drug that has extended stability up to one year compared to the reference drug (weeks) and has comparable dissolution rate (bioavailability) The novel form is patented and being scaled up for clinical trials and biological studies The additive used to stabilize the anticancer drug is a safe chemical (from the GRAS list of FDA) Chalk2Salt team won Rs. 5 lac award at the Power of Ideas country-wide competition for innovative business plans in October Received Mentoring and Business planning sessions at IIM-A

6 Chalk2Salt Take insoluble drugs like chalk dust and transform them into highly soluble solid forms as table salt Outstanding track record of Science and Business Dr. Ashwini Nangia, PhD Professor of Chemistry University of Hyderabad Ms. Monika Verma, MSc CEO Avancé Phytopharmaceuticals Dr. Shiv Prakash Rathnam, PhD MD Synchron Research Clinical Research CRO 6

7 Genesis of Team Met at BioBio conference in March 2010 at Hyd Explored a tie up for solid form drug development, clinical trials, and out licensing opportunities May 2010 Chalk2Salt was born Crystalin Research, a TBI@UoH incubatee Avancé Phytopharmaceuticals Synchron Clinical Research Working with a basket of APIs to mitigate risk R&D and launch 10 new improved drug products over next 3 years

8 OUR UNIQUE BUSINESS MODEL Improved Chemical Entities (ICEs) Drug discovery is expensive and uncertain 12 years and $ 1.2 bn to bring a new drug to market 40% marketed drugs have poor water solubility 80-90% molecules in R&D will pose solubility issues We will do quick ROI research Develop Cocrystal forms of insoluble drugs (ICEs) Conduct scale up to pre-clinical & clinical research Out-License ICE products to pharma companies Cocrystal drug products enjoy 3 to 5 yrs exclusivity No other company offering value-added product Launching R&D lab at TBI@UoH, a DST initiative 8

9 Pharmaceutical Licensing Hot product : Temozolomide Blockbuster anticancer Drug Crossed a billion dollar market We have developed improved version of it License value : 20 mn USD by 2014 (Rs 100 Cr) R&D Investment : Rs 6 Crore

10 Investment Required for Temozolomide Toxicology Studies: Rs 2 Crore Pre-clinical: Rs 25 Lakh Phase I Studies: Rs 1 Crore Phase II Studies: Rs 3 Crore Total : Rs 6 Crore Duration : 3 Years 10

11 Best Indian Team Chalk2Salt BioPharm 2020: UK-India Biotech-Pharma Business Challenge University of Nottingham, 3 rd September 2010 Panel Chair Stefano Pessina, CEO Alliance Boots it will bring drug products to the market which were left aside it could have a strong impact on the pharma industry cost wise it will have a clear impact on the health of people

12 BioPharm 2020 has experienced a number of challenges and learnings for on-going and future international collaborations Developing mutually valuable relationships with new industry partners takes time and effort to build, nurture and maintain. Leveraged the relationships of our collaborating partners RCUK, international UKTI, and those within our Advisory Board to broker introductions and open doors. Creation of an environment where cultural differences (approach & style of working, language etc) are known and understood between collaborators, but also takes time Competing demands and priorities from other research grants and typical international travel patterns and teaching requirements of PIs limits opportunity for the most valuable interaction - face to face Infrastructure for effective communications needs careful planning Our 3 way bridge (UK, Bangalore, Kanpur) has given rise to a number of communication challenges

13 We are mid way through our programme and future opportunities are already presenting themselves Increased industry engagement Broadening our reach between UK and India (Jawaharlal Nehru Centre for Advanced Scientific Research Karnataka, Bangalore) Extending bridge to China Business Start-Ups We will continue to liaise with competition finalist and winning teams to discuss business start up progress Long term - drive new business opportunities through translational research spin-out company formation